Zurück
www.finanzen.net/nachricht/aktien/...enheimer-analyst-6386702
Anzeige
Meldung des Tages: Breaking News: Das “Schweizer Messer” für Diabetiker ist da!
Strongbrigde Biopharma 200 Prozent Potential?
Beiträge:
46
Zugriffe: 19.003 / Heute: 2
Zugriffe: 19.003 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +61,04%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +58,93%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +58,89%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +51,40%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +49,01%
www.analystratings.com/articles/...gbridge-biopharma-plc-sbbp/
www.analystratings.com/articles/...a-buy-from-h-c-wainwright/
www.zacks.com/stock/news/608278/...=CS-ZC-FT-tale_of_the_tape|yseop_template_4-608278
scheint nur eine Richtung zu kennen! Zumindest aktuell
ich versuche das „aktuell“ auszublenden und mich auf „langfristig“ zu konzentrieren. Die Bewertung ist doch m.E. derzeit eher ein Witz. Vllt gelingt es mir ja, nicht ständig ins Depot zu schauen.
Von Tief zu Tief....Finger weg! Meine Meinung.
www.finanzen.net/nachricht/aktien/...nen-quartals-vor-8556399
seekingalpha.com/news/...eed_news_all&utm_medium=referral
www.analystratings.com/articles/...rongbridge-biopharma-sbbp/
seekingalpha.com/article/...bing-the-strongbridge-acquisition
www.pharmatimes.com/news/...n_becomes_available_in_uk_1385622
www.pharmatimes.com/news/...n_becomes_available_in_uk_1385622
seekingalpha.com/news/...eed_news_all&utm_medium=referral
www.nasdaq.com/de/market-activity/stocks/xers/real-time
Now what
Cushing's syndrome is rare, but patients display a variety of symptoms usually associated with more common diseases, including elevated blood pressure and blood sugar. As such, it's often misdiagnosed. The availability of a new tablet to treat the disorder could bring enough patients out of the woodwork to drive annual sales above $200 million in a few short years.
Recorlev wasn't the only rare disease drug Xeris acquired from Strongbridge. The company also picked up Keveyis. This is the first and only available treatment approved by the FDA to treat primary periodic paralysis.
During the first nine months of 2021, Keveyis sales rose 33% year over year to $30 million. With the addition of Recorlev to Xeris' product line, the company could feasibly begin generating annual sales above $100 million before the end of 2023.
At recent prices, Xeris Biopharma sports a very modest market cap of just $366 million. That seems extremely cheap for a company with several commercial-stage products. I wouldn't be surprised if this biotech stock shoots through the roof in the new year.
www.fool.com/investing/2021/12/31/...-stock-is-jumping-today/
Cushing's syndrome is rare, but patients display a variety of symptoms usually associated with more common diseases, including elevated blood pressure and blood sugar. As such, it's often misdiagnosed. The availability of a new tablet to treat the disorder could bring enough patients out of the woodwork to drive annual sales above $200 million in a few short years.
Recorlev wasn't the only rare disease drug Xeris acquired from Strongbridge. The company also picked up Keveyis. This is the first and only available treatment approved by the FDA to treat primary periodic paralysis.
During the first nine months of 2021, Keveyis sales rose 33% year over year to $30 million. With the addition of Recorlev to Xeris' product line, the company could feasibly begin generating annual sales above $100 million before the end of 2023.
At recent prices, Xeris Biopharma sports a very modest market cap of just $366 million. That seems extremely cheap for a company with several commercial-stage products. I wouldn't be surprised if this biotech stock shoots through the roof in the new year.
www.fool.com/investing/2021/12/31/...-stock-is-jumping-today/
www.finanzen.net/nachricht/aktien/...hing-s-syndrome-10922686
20 Prozent in einem Monat ist aktuell für einen Biotechtitel nicht schlecht, zumindest wenn es gen Norden geht! Aber nachhaltig sollten die 2,90 / 3 Dollar noch aus dem Weg geräumt werden...
www.nasdaq.com/de/market-activity/stocks/xers/real-time
www.nasdaq.com/de/market-activity/stocks/xers/real-time
www.nasdaq.com/articles/...-04-2024%3A-sem-xers-rxrx-omga-nvo
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Xeris Biopharma Holdings Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 83 | Xeris Pharmaceutical | centsucher | Biotecfan | 15.10.25 21:29 | |
| 45 | Strongbrigde Biopharma 200 Prozent Potential? | Balu4u | Balu4u | 05.01.24 10:43 |